Compare Apollo Global Management Ord Shs (APO) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apollo Global Management Ord Shs vs Merck & Co., Inc. — how do they compare? Apollo Global Management Ord Shs trades at $119.97 (market cap $69.38B), while Merck & Co., Inc. trades at $124.07 (market cap $305.12B). The key difference: Merck & Co., Inc. is far larger — about 4.4× Apollo Global Management Ord Shs's market cap, and Merck & Co., Inc. pays the higher dividend (2.75%). Which is the better fit depends on your goals.
| APO | MRK | |
|---|---|---|
Market Cap | $69.38B | $305.12B |
Sector | Financials | Health |
52-Week High | $156.05 | $129.52 |
52-Week Low | $100.30 | $77.60 |
Enterprise Value | -$168.19B | $348.54B |
Dividend Yield | 1.87% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apollo Global Management (APO) trades at $120.34, up 0.42% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $1.94, beating estimates, and maintains strong analyst support with 23 buy ratings. Recent news highlights private credit growth opportunities alongside liquidity concerns in Apollo's funds.
APO's outlook is supported by earnings beats and a $149.86 consensus price target, but risks include private credit liquidity pressures and a high P/E ratio of 75.69. Investor sentiment is mixed due to ongoing fund withdrawal caps and legal investigations, though long-term growth in alternative assets remains a positive catalyst.
Merck (MRK) trades at $123.585, up 0.04% on the day, with a bullish technical signal and strong institutional interest. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a favorable analyst consensus.
The outlook for MRK is positive, supported by earnings beats, a high analyst buy rating (67.57%), and a consensus price target of $135.14. Key risks include rising debt levels and potential regulatory pressures, but the stock's solid fundamentals and acquisition strategy present a compelling opportunity for growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
